Staff Nathan P, Grisold Anna, Grisold Wolfgang, Windebank Anthony J
Department of Neurology, Mayo Clinic, Rochester, MN.
Department of Neurology, Medical University of Vienna, Vienna, Austria.
Ann Neurol. 2017 Jun;81(6):772-781. doi: 10.1002/ana.24951. Epub 2017 Jun 5.
Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting side effect experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients treated with neurotoxic chemotherapy will develop CIPN, and there is considerable variability in its severity between patients. It is often sensory-predominant with pain and can lead to long-term morbidity in survivors. The prevalence and burden of CIPN late effects will likely increase as cancer survival rates continue to improve. In this review, we discuss the approach to peripheral neuropathy in patients with cancer and address the clinical phenotypes and pathomechanisms of specific neurotoxic chemotherapeutic agents. Ann Neurol 2017;81:772-781.
化疗引起的周围神经病变（CIPN）是接受癌症治疗的患者常见的剂量限制性副作用。接受神经毒性化疗的患者中约有30%至40%会发生CIPN，且患者之间其严重程度存在很大差异。它通常以感觉为主，伴有疼痛，并可导致幸存者出现长期发病情况。随着癌症生存率持续提高，CIPN晚期效应的患病率和负担可能会增加。在本综述中，我们讨论了癌症患者周围神经病变的处理方法，并阐述了特定神经毒性化疗药物的临床表型和发病机制。《神经病学纪事》2017年；81:772 - 781。
